Closed 32 of 35 events
Threads / Desogestrel Contraceptive Reclassification / Timeline
Lifecycle stage Response Published
1,393 days in stage

Desogestrel Contraceptive Reclassification

The Medicines and Healthcare products Regulatory Agency is considering reclassifying desogestrel contraceptives from prescription-only to pharmacy-available status to improve access to long-acting reversible contraception (LARC) and address barriers in commissioning. The issue is linked to the Access to Contraceptive Services Bill and aims to reduce unnecessary gynaecology waiting lists and improve equity of access.

Log in for AI briefing
Showing 32 of 35 signals
Sort Latest first Oldest first
Family 1
Signal
Year
Body
Role
Clear all
Family: Consultations

2022

6 events
20 Jul 2022 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Consultation on proposal to make Gina 10 microgram vaginal tablets (Estradiol) available from pharmacies — outcome published

Public consultation on a set of proposals to make Gina 10 microgram vaginal tablets (Estradiol) available from pharmacies.

▤ View document · ↗ GOV.UK · ↓ Proposal to make Gina 10 microgram vaginal tabl…
+6 more
↓ Gina - Patient Information Leaflet (2pp) ↓ Gina - Pharmacy Checklist (14pp) ↓ Gina - Carton label (3pp) ↓ Gina - Summary of Product Characteristics (12pp) ↓ Summary of responses to consultation - Gina 10 microgram va… ↓ Public Assessment Report - Prescription Only Medicine to Ph…
23 Feb 2022 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Consultation on proposal to make Gina 10 microgram vaginal tablets (Estradiol) available from pharmacies — consultation closed

Public consultation on a set of proposals to make Gina 10 microgram vaginal tablets (Estradiol) available from pharmacies.

▤ View document · ↗ GOV.UK · ↓ Proposal to make Gina 10 microgram vaginal tabl…
+6 more
↓ Gina - Patient Information Leaflet (2pp) ↓ Gina - Pharmacy Checklist (14pp) ↓ Gina - Carton label (3pp) ↓ Gina - Summary of Product Characteristics (12pp) ↓ Summary of responses to consultation - Gina 10 microgram va… ↓ Public Assessment Report - Prescription Only Medicine to Ph…
2 Feb 2022 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Consultation on proposal to make Gina 10 microgram vaginal tablets (Estradiol) available from pharmacies — consultation opened

Public consultation on a set of proposals to make Gina 10 microgram vaginal tablets (Estradiol) available from pharmacies.

▤ View document · ↗ GOV.UK · ↓ Proposal to make Gina 10 microgram vaginal tabl…
+6 more
↓ Gina - Patient Information Leaflet (2pp) ↓ Gina - Pharmacy Checklist (14pp) ↓ Gina - Carton label (3pp) ↓ Gina - Summary of Product Characteristics (12pp) ↓ Summary of responses to consultation - Gina 10 microgram va… ↓ Public Assessment Report - Prescription Only Medicine to Ph…

2021

11 events
8 Jul 2021 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Lovima 75 microgram film-coated tablets (Desogestrel): Public Consultation — outcome published

A 3-week consultation on a proposal to make Lovima 75 microgram film-coated tablets (Desogestrel) available from pharmacies.

▤ View document · ↗ GOV.UK · ↓ Lovima public consultation document
+8 more
↓ Annex 1: Response document for MHRA public consultation on … ↓ Annex 2: Lovima leaflet (2pp) ↓ Annex 3: Lovima Label (3pp) ↓ Annex 4: Lovima SPC (13pp) ↓ Annex 5: Lovima checklist (2pp) ↓ Data Protection and Privacy Information ↓ Lovima public assessment report ↓ A public consultation on reclassifying two medicines contai…
8 Jul 2021 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Hana 75 microgram film-coated tablets (Desogestrel): Public Consultation — outcome published

A 3-week public consultation on a proposal to make Hana 75 microgram film-coated tablets (Desogestrel) available from pharmacies.

▤ View document · ↗ GOV.UK · ↓ Hana public consultation document
+8 more
↓ Annex 1: Response document for MHRA public consultation on … ↓ Annex 2: Hana leaflet (2pp) ↓ Annex 3: Hana Label (4pp) ↓ Annex 4: Hana SPC (14pp) ↓ Annex 5: Hana checklist (5pp) ↓ Data Protection and Privacy Information ↓ Hana public assessment report ↓ A public consultation on reclassifying two medicines contai…
5 Mar 2021 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Lovima 75 microgram film-coated tablets (Desogestrel): Public Consultation — consultation closed

A 3-week consultation on a proposal to make Lovima 75 microgram film-coated tablets (Desogestrel) available from pharmacies.

▤ View document · ↗ GOV.UK · ↓ Lovima public consultation document
+8 more
↓ Annex 1: Response document for MHRA public consultation on … ↓ Annex 2: Lovima leaflet (2pp) ↓ Annex 3: Lovima Label (3pp) ↓ Annex 4: Lovima SPC (13pp) ↓ Annex 5: Lovima checklist (2pp) ↓ Data Protection and Privacy Information ↓ Lovima public assessment report ↓ A public consultation on reclassifying two medicines contai…
5 Mar 2021 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Hana 75 microgram film-coated tablets (Desogestrel): Public Consultation — consultation closed

A 3-week public consultation on a proposal to make Hana 75 microgram film-coated tablets (Desogestrel) available from pharmacies.

▤ View document · ↗ GOV.UK · ↓ Hana public consultation document
+8 more
↓ Annex 1: Response document for MHRA public consultation on … ↓ Annex 2: Hana leaflet (2pp) ↓ Annex 3: Hana Label (4pp) ↓ Annex 4: Hana SPC (14pp) ↓ Annex 5: Hana checklist (5pp) ↓ Data Protection and Privacy Information ↓ Hana public assessment report ↓ A public consultation on reclassifying two medicines contai…
12 Feb 2021 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Lovima 75 microgram film-coated tablets (Desogestrel): Public Consultation — consultation opened

A 3-week consultation on a proposal to make Lovima 75 microgram film-coated tablets (Desogestrel) available from pharmacies.

▤ View document · ↗ GOV.UK · ↓ Lovima public consultation document
+8 more
↓ Annex 1: Response document for MHRA public consultation on … ↓ Annex 2: Lovima leaflet (2pp) ↓ Annex 3: Lovima Label (3pp) ↓ Annex 4: Lovima SPC (13pp) ↓ Annex 5: Lovima checklist (2pp) ↓ Data Protection and Privacy Information ↓ Lovima public assessment report ↓ A public consultation on reclassifying two medicines contai…
12 Feb 2021 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Hana 75 microgram film-coated tablets (Desogestrel): Public Consultation — consultation opened

A 3-week public consultation on a proposal to make Hana 75 microgram film-coated tablets (Desogestrel) available from pharmacies.

▤ View document · ↗ GOV.UK · ↓ Hana public consultation document
+8 more
↓ Annex 1: Response document for MHRA public consultation on … ↓ Annex 2: Hana leaflet (2pp) ↓ Annex 3: Hana Label (4pp) ↓ Annex 4: Hana SPC (14pp) ↓ Annex 5: Hana checklist (5pp) ↓ Data Protection and Privacy Information ↓ Hana public assessment report ↓ A public consultation on reclassifying two medicines contai…

2019

1 event
1 Aug 2019 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Proposal to make Colourstart Test 65mcg Cutaneous Patch available from general sales outlets without prescription — outcome published

We are considering making Colourstart Test 65mcg Cutaneous Patch available to buy without prescription from retail outlets. We always want to involve the public and healthcare professionals in decisions that affect them. We want to know what you think about …

▤ View document · ↗ GOV.UK · ↓ Colourstart consultation document (28pp)
+7 more
↓ Colourstart consultation response form ↓ Colourstart public assessment report (15pp) ↓ Colourstart BAD response (15pp) ↓ Colourstart BSCA response (15pp) ↓ Colourstart NPA response (2pp) ↓ Colourstart RPS response (2pp) ↓ Colourstart CCA response (1pp)

2018

2 events
7 Nov 2018 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Proposal to make Colourstart Test 65mcg Cutaneous Patch available from general sales outlets without prescription — consultation closed

We are considering making Colourstart Test 65mcg Cutaneous Patch available to buy without prescription from retail outlets. We always want to involve the public and healthcare professionals in decisions that affect them. We want to know what you think about …

▤ View document · ↗ GOV.UK · ↓ Colourstart consultation document (28pp)
+7 more
↓ Colourstart consultation response form ↓ Colourstart public assessment report (15pp) ↓ Colourstart BAD response (15pp) ↓ Colourstart BSCA response (15pp) ↓ Colourstart NPA response (2pp) ↓ Colourstart RPS response (2pp) ↓ Colourstart CCA response (1pp)
17 Oct 2018 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Proposal to make Colourstart Test 65mcg Cutaneous Patch available from general sales outlets without prescription — consultation opened

We are considering making Colourstart Test 65mcg Cutaneous Patch available to buy without prescription from retail outlets. We always want to involve the public and healthcare professionals in decisions that affect them. We want to know what you think about …

▤ View document · ↗ GOV.UK · ↓ Colourstart consultation document (28pp)
+7 more
↓ Colourstart consultation response form ↓ Colourstart public assessment report (15pp) ↓ Colourstart BAD response (15pp) ↓ Colourstart BSCA response (15pp) ↓ Colourstart NPA response (2pp) ↓ Colourstart RPS response (2pp) ↓ Colourstart CCA response (1pp)

2017

7 events
28 Nov 2017 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Proposal to make Sildenafil 50mg film-coated tablets available from Pharmacies — outcome published

We are considering making Sildenafil 50mg film-coated tablets available to buy from pharmacies. We always want to involve the public and healthcare professionals in decisions that affect them. We want to know what you think about this change.

▤ View document · ↗ GOV.UK · ↓ Sildenafil public reclassification report for c… (33pp)
+3 more
↓ Sildenafil response form ↓ Viagra Connect reclassification public assessment report (14pp) ↓ Summary table of responses on proposed POM to P reclassific… (18pp)
17 Aug 2017 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Proposal to make Dovonex Psoriasis Ointment available from Pharmacies — outcome published

We are considering making Dovonex Psoriasis 50 microgram/g Ointment available to buy from pharmacies. We always want to involve the public and healthcare professionals in decisions that affect them. We want to know what you think about this change.

▤ View document · ↗ GOV.UK · ↓ Dovonex Psoriasis Ointment public consultation (22pp)
+12 more
↓ Dovonex Psoriasis Ointment response document ↓ Dovonex Psoriasis Ointment Public Assessment Report (12pp) ↓ Dispensing Doctor’s Association (DDA) response (1pp) ↓ British Association of Dermatologists (BAD) response (2pp) ↓ Psoriasis and Psoriatic Arthritis Association (PAPAA) respo… (2pp) ↓ National Pharmacy Association (NPA) response (2pp) ↓ Proprietary Association of Great Britain (PAGB) response (2pp) ↓ Royal Pharmaceutical Society (RPS) response (1pp) ↓ Dermatology Pharmacist response (1pp) ↓ Patient response (2pp) ↓ Patient 3 response (2pp) ↓ Patient 2 response (2pp)
5 Jul 2017 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Reclassification of Otrivine extra dual relief nasal spray solution (ARM 90) — outcome published

MHRA is asking for feedback on proposals to change the legal classification of Otrivine extra dual relief nasal spray solution from prescription only medicine (POM) to pharmacy only (P).

▤ View document · ↗ GOV.UK · ↓ Consultation document: ARM 90 Otrivine extra du… (21pp)
+4 more
↓ Otrivine Extra Reclassification Public Assessment Report ↓ Guild of Healthcare Pharmacists response (2pp) ↓ Royal Pharmaceutical Society response (3pp) ↓ Medical Rescue Limited Response (1pp)
20 Apr 2017 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Proposal to make Dovonex Psoriasis Ointment available from Pharmacies — consultation closed

We are considering making Dovonex Psoriasis 50 microgram/g Ointment available to buy from pharmacies. We always want to involve the public and healthcare professionals in decisions that affect them. We want to know what you think about this change.

▤ View document · ↗ GOV.UK · ↓ Dovonex Psoriasis Ointment public consultation (22pp)
+12 more
↓ Dovonex Psoriasis Ointment response document ↓ Dovonex Psoriasis Ointment Public Assessment Report (12pp) ↓ Dispensing Doctor’s Association (DDA) response (1pp) ↓ British Association of Dermatologists (BAD) response (2pp) ↓ Psoriasis and Psoriatic Arthritis Association (PAPAA) respo… (2pp) ↓ National Pharmacy Association (NPA) response (2pp) ↓ Proprietary Association of Great Britain (PAGB) response (2pp) ↓ Royal Pharmaceutical Society (RPS) response (1pp) ↓ Dermatology Pharmacist response (1pp) ↓ Patient response (2pp) ↓ Patient 3 response (2pp) ↓ Patient 2 response (2pp)
18 Apr 2017 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Proposal to make Sildenafil 50mg film-coated tablets available from Pharmacies — consultation closed

We are considering making Sildenafil 50mg film-coated tablets available to buy from pharmacies. We always want to involve the public and healthcare professionals in decisions that affect them. We want to know what you think about this change.

▤ View document · ↗ GOV.UK · ↓ Sildenafil public reclassification report for c… (33pp)
+3 more
↓ Sildenafil response form ↓ Viagra Connect reclassification public assessment report (14pp) ↓ Summary table of responses on proposed POM to P reclassific… (18pp)
30 Mar 2017 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Proposal to make Dovonex Psoriasis Ointment available from Pharmacies — consultation opened

We are considering making Dovonex Psoriasis 50 microgram/g Ointment available to buy from pharmacies. We always want to involve the public and healthcare professionals in decisions that affect them. We want to know what you think about this change.

▤ View document · ↗ GOV.UK · ↓ Dovonex Psoriasis Ointment public consultation (22pp)
+12 more
↓ Dovonex Psoriasis Ointment response document ↓ Dovonex Psoriasis Ointment Public Assessment Report (12pp) ↓ Dispensing Doctor’s Association (DDA) response (1pp) ↓ British Association of Dermatologists (BAD) response (2pp) ↓ Psoriasis and Psoriatic Arthritis Association (PAPAA) respo… (2pp) ↓ National Pharmacy Association (NPA) response (2pp) ↓ Proprietary Association of Great Britain (PAGB) response (2pp) ↓ Royal Pharmaceutical Society (RPS) response (1pp) ↓ Dermatology Pharmacist response (1pp) ↓ Patient response (2pp) ↓ Patient 3 response (2pp) ↓ Patient 2 response (2pp)
27 Mar 2017 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Proposal to make Sildenafil 50mg film-coated tablets available from Pharmacies — consultation opened

We are considering making Sildenafil 50mg film-coated tablets available to buy from pharmacies. We always want to involve the public and healthcare professionals in decisions that affect them. We want to know what you think about this change.

▤ View document · ↗ GOV.UK · ↓ Sildenafil public reclassification report for c… (33pp)
+3 more
↓ Sildenafil response form ↓ Viagra Connect reclassification public assessment report (14pp) ↓ Summary table of responses on proposed POM to P reclassific… (18pp)

2015

3 events
19 Mar 2015 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Reclassification of Otrivine extra dual relief nasal spray solution (ARM 90) — consultation closed

MHRA is asking for feedback on proposals to change the legal classification of Otrivine extra dual relief nasal spray solution from prescription only medicine (POM) to pharmacy only (P).

▤ View document · ↗ GOV.UK · ↓ Consultation document: ARM 90 Otrivine extra du… (21pp)
+4 more
↓ Otrivine Extra Reclassification Public Assessment Report ↓ Guild of Healthcare Pharmacists response (2pp) ↓ Royal Pharmaceutical Society response (3pp) ↓ Medical Rescue Limited Response (1pp)
25 Feb 2015 | Consultation outcome Medicines and Healthcare products Regulatory Agency linked

Reclassification of Otrivine extra dual relief nasal spray solution (ARM 90) — consultation opened

MHRA is asking for feedback on proposals to change the legal classification of Otrivine extra dual relief nasal spray solution from prescription only medicine (POM) to pharmacy only (P).

▤ View document · ↗ GOV.UK · ↓ Consultation document: ARM 90 Otrivine extra du… (21pp)
+4 more
↓ Otrivine Extra Reclassification Public Assessment Report ↓ Guild of Healthcare Pharmacists response (2pp) ↓ Royal Pharmaceutical Society response (3pp) ↓ Medical Rescue Limited Response (1pp)

2014

2 events